share_log

Medtronic | 8-K: Current report

Medtronic | 8-K: Current report

美敦力 | 8-K：重大事件
美股SEC公告 ·  2024/08/20 18:49

Moomoo AI 已提取核心信息

Medtronic reported Q1 FY25 revenue of $7.9 billion, increasing 2.8% as reported and 5.3% organic. GAAP diluted EPS rose 36% to $0.80, while non-GAAP diluted EPS grew 3% to $1.23. Growth was driven by strong performance across multiple franchises, including Cardiac Ablation Solutions, Neuromodulation, Spine, Structural Heart, and Diabetes.The Cardiovascular Portfolio led growth with 6.9% organic increase, followed by Neuroscience at 5.3% and Diabetes at 12.6%. Notable product innovations included the PulseSelect pulsed field ablation system, Evolut FX+ TAVR system, and MiniMed 780G automated insulin delivery system. The U.S. Diabetes segment showed particular strength with mid-teens growth.Based on strong Q1 performance, Medtronic raised its FY25 guidance, projecting organic revenue growth of 4.5-5% (up from 4-5%) and non-GAAP diluted EPS of $5.42-$5.50 (previously $5.40-$5.50). The company expects sustained growth from new product introductions while continuing strategic investments to support launches.
Medtronic reported Q1 FY25 revenue of $7.9 billion, increasing 2.8% as reported and 5.3% organic. GAAP diluted EPS rose 36% to $0.80, while non-GAAP diluted EPS grew 3% to $1.23. Growth was driven by strong performance across multiple franchises, including Cardiac Ablation Solutions, Neuromodulation, Spine, Structural Heart, and Diabetes.The Cardiovascular Portfolio led growth with 6.9% organic increase, followed by Neuroscience at 5.3% and Diabetes at 12.6%. Notable product innovations included the PulseSelect pulsed field ablation system, Evolut FX+ TAVR system, and MiniMed 780G automated insulin delivery system. The U.S. Diabetes segment showed particular strength with mid-teens growth.Based on strong Q1 performance, Medtronic raised its FY25 guidance, projecting organic revenue growth of 4.5-5% (up from 4-5%) and non-GAAP diluted EPS of $5.42-$5.50 (previously $5.40-$5.50). The company expects sustained growth from new product introductions while continuing strategic investments to support launches.
美敦力报告称2025财年第一季度营业收入为79亿，报告增长2.8%，有机增长5.3%。根据美国通用会计准则（GAAP）摊薄后每股收益上升36%，达到0.80美元，而非GAAP摊薄后每股收益增长3%，达到1.23美元。增长得益于多个业务领域的强劲表现，包括心脏消融解决方案、神经调节、脊柱、结构性心脏和糖尿病。心血管产品组合引领增长，有机增长6.9%，神经科学增长5.3%，糖尿病增长12.6%。值得注意的产品创新包括PulseSelect脉冲场消融系统、Evolut FX+经导管主动脉瓣置换（TAVR）系统和MiniMed 780G自动胰岛素输送系统。美国糖尿病业务部门表现尤其强劲，增长中段达到两...展开全部
美敦力报告称2025财年第一季度营业收入为79亿，报告增长2.8%，有机增长5.3%。根据美国通用会计准则（GAAP）摊薄后每股收益上升36%，达到0.80美元，而非GAAP摊薄后每股收益增长3%，达到1.23美元。增长得益于多个业务领域的强劲表现，包括心脏消融解决方案、神经调节、脊柱、结构性心脏和糖尿病。心血管产品组合引领增长，有机增长6.9%，神经科学增长5.3%，糖尿病增长12.6%。值得注意的产品创新包括PulseSelect脉冲场消融系统、Evolut FX+经导管主动脉瓣置换（TAVR）系统和MiniMed 780G自动胰岛素输送系统。美国糖尿病业务部门表现尤其强劲，增长中段达到两位数。基于强劲的第一季度表现，美敦力提升了2025财年指导，预计有机营业收入增长为4.5%-5%（从4%-5%上调）和非GAAP摊薄后每股收益为5.42美元-5.50美元（之前为5.40美元-5.50美元）。公司预计将从新产品的推出中持续增长，同时继续进行战略投资以支持产品发布。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    PAVmed
    PAVMZ
    -- 0.0162
    Allurion Technologies
    ALUR
    -- 3.700
    Baird Medical Investment Holdings
    BDMD
    -- 8.150
    Adagio Medical
    ADGM
    -- 0.921
    Bluejay Diagnostics
    BJDX
    -- 4.0000
    解锁完整榜单
    热门中概股
    追踪最热门的中概股实时资讯。
    热门讨论
    中美谈话新契机，通胀不再？
    🎙️讨论： 1. 你认为特朗普上台后，对华政策将如何影响中国资产？ 2. 美股市场通胀风险下降，有哪些利好板块？ 展开
    中国将在未来一年采取"适度宽松"的货币政策，这是自2011年以来的首次转向宽松。